American CryoStem Announces FDA Approval of IND to Commence Phase I Clinical Trial for Long COVID/Post-Acute Sequelae of SARS-CoV-2 (PASC)
Eatontown, New Jersey--(Newsfile Corp. - January 6, 2023) - American CryoStem Corporation (OTC Pink: CRYO), a clinical-stage therapeutics company with a proprietary end-to-end core biotechnology platform of tissue-based cellular technologies that powers its clinical pipeline, announced today that it has received U.S. Food and Drug Administration (FDA) approval to proceed with a Phase I Clinical Trial for the treatment of Long COVID/PASC. The IND titled "A Pilot Study on Research Treatment of...
2023-01-06 7:00 AM EST
American CryoStem Announces the Addition of Agustin Legido, MD, PhD, MBA to Its Advisory Board
Eatontown, New Jersey--(Newsfile Corp. - December 22, 2022) - American CryoStem Corporation (OTC Pink: CRYO), a clinical-stage therapeutics company with a proprietary end-to-end core biotechnology platform of tissue-based cellular technologies powering its clinical pipeline, announced today that Agustin Legido, MD, PhD, MBA has joined its Scientific and Medical Advisory Board. Dr. Legido, a pediatric neurologist who holds a PhD in biochemical endocrinology, is Board Certified by the Board of...
2022-12-22 7:00 AM EST